Published in BMJ on February 28, 2012
Urinary incontinence after treatment for prostate cancer. BMJ (2011) 1.38
Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol (2012) 6.09
EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol (2013) 4.89
Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol (2010) 4.45
EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol (2004) 3.72
Systematic review of complications of prostate biopsy. Eur Urol (2013) 3.66
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol (2013) 3.34
Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol (2012) 3.30
Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. J Urol (2012) 3.01
Hospital admissions after transrectal ultrasound-guided biopsy of the prostate in men diagnosed with prostate cancer: a database analysis in England. Int J Urol (2014) 2.72
Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol (2011) 2.61
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int (2010) 2.59
TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer. BJU Int (2013) 2.44
MR to ultrasound registration for image-guided prostate interventions. Med Image Anal (2010) 2.07
How good is MRI at detecting and characterising cancer within the prostate? Eur Urol (2006) 2.07
Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol (2012) 2.05
Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer. J Urol (2012) 1.99
Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol (2009) 1.87
The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. BJU Int (2010) 1.74
Charlson scores based on ICD-10 administrative data were valid in assessing comorbidity in patients undergoing urological cancer surgery. J Clin Epidemiol (2006) 1.73
Visually directed high-intensity focused ultrasound for organ-confined prostate cancer: A proposed standard for the conduct of therapy. BJU Int (2006) 1.68
Self management for men with lower urinary tract symptoms: randomised controlled trial. BMJ (2006) 1.66
Photodynamic therapy for prostate cancer--a review of current status and future promise. Nat Clin Pract Urol (2009) 1.62
Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int (2007) 1.61
Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol (2003) 1.58
Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int (2011) 1.54
Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment. BMJ (2004) 1.54
Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. J Urol (2002) 1.51
The relationship between objective frequency-volume chart data and the I-PSS in men with lower urinary tract symptoms. Eur Urol (2007) 1.51
The influence of family history on prostate cancer risk: implications for clinical management. BJU Int (2010) 1.48
A description of radical nephrectomy practice and outcomes in England: 1995-2002. BJU Int (2005) 1.46
Focal therapy for prostate cancer: a potential strategy to address the problem of overtreatment. Arch Esp Urol (2010) 1.44
Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard. Radiology (2013) 1.39
Multicenter study evaluating extraprostatic uptake of 11C-choline, 18F-methylcholine, and 18F-ethylcholine in male patients: physiological distribution, statistical differences, imaging pearls, and normal variants. Nucl Med Commun (2015) 1.39
Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int (2011) 1.37
Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Crit Rev Oncol Hematol (2010) 1.34
Will focal therapy become a standard of care for men with localized prostate cancer? Nat Clin Pract Oncol (2007) 1.31
A systematic review and critique of the literature relating hospital or surgeon volume to health outcomes for 3 urological cancer procedures. J Urol (2004) 1.31
Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? Lancet Oncol (2012) 1.18
Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway? J Magn Reson Imaging (2012) 1.18
The accuracy of different biopsy strategies for the detection of clinically important prostate cancer: a computer simulation. J Urol (2012) 1.17
MR imaging of prostate after treatment with high-intensity focused ultrasound. Radiology (2008) 1.15
Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy: a pilot study. Cancer (2012) 1.11
Modelling prostate motion for data fusion during image-guided interventions. IEEE Trans Med Imaging (2011) 1.08
Mortality in men admitted to hospital with acute urinary retention: database analysis. BMJ (2007) 1.08
The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. BJU Int (2008) 1.07
Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy. BJU Int (2010) 1.06
Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer. BJU Int (2012) 1.05
Incidence of primary and recurrent acute urinary retention between 1998 and 2003 in England. J Urol (2006) 1.04
A biomedical engineering approach to mitigate the errors of prostate biopsy. Nat Rev Urol (2012) 1.02
Detection, localisation and characterisation of prostate cancer by prostate HistoScanning(™). BJU Int (2011) 1.01
The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management. BJU Int (2005) 1.00
Multi-parametric magnetic resonance imaging to rule-in and rule-out clinically important prostate cancer in men at risk: a cohort study. Urol Int (2011) 0.98
The accuracy of transrectal ultrasonography supplemented with computer-aided ultrasonography for detecting small prostate cancers. BJU Int (2008) 0.98
Defining the components of a self-management programme for men with uncomplicated lower urinary tract symptoms: a consensus approach. Eur Urol (2004) 0.97
An analysis of the Research Fellowship Scheme of the Royal College of Surgeons of England. J Am Coll Surg (2005) 0.97
Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction. BJU Int (2005) 0.97
Can MRI replace serial biopsies in men on active surveillance for prostate cancer? Curr Opin Urol (2014) 0.94
Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. BJU Int (2008) 0.94
Image-directed, tissue-preserving focal therapy of prostate cancer: a feasibility study of a novel deformable magnetic resonance-ultrasound (MR-US) registration system. BJU Int (2013) 0.94
Multiparametric magnetic resonance imaging in the management and diagnosis of prostate cancer: current applications and strategies. Curr Urol Rep (2014) 0.93
MRI-targeted prostate biopsy: a review of technique and results. Nat Rev Urol (2013) 0.93
Minimally-invasive technologies in uro-oncology: the role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer. Surg Oncol (2009) 0.92
A novel tissue engineered three-dimensional in vitro colorectal cancer model. Acta Biomater (2013) 0.91
Management of low risk prostate cancer: active surveillance and focal therapy. Curr Opin Urol (2014) 0.91
The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int (2006) 0.90
Logistic regression model for diagnosis of transition zone prostate cancer on multi-parametric MRI. Eur Radiol (2014) 0.90
Men's experiences of having lower urinary tract symptoms: factors relating to bother. BJU Int (2004) 0.89
Active surveillance for low-risk prostate cancer. Crit Rev Oncol Hematol (2012) 0.89
Men and chronic illness: a qualitative study of LUTS. J Health Psychol (2004) 0.89
Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way? World J Urol (2008) 0.88
Frequency volume charts should be used in men with lower urinary tract symptoms. Int J Surg (2005) 0.88
Threshold volumes for urological cancer surgery: a survey of UK urologists. BJU Int (2004) 0.87
The role of MRI in active surveillance of prostate cancer. Curr Opin Urol (2013) 0.87
[International comparison of guidelines for the management of benign prostatic hyperplasia: use of a validated generic tool]. Prog Urol (2004) 0.86
Histological outcomes after focal high-intensity focused ultrasound and cryotherapy. World J Urol (2015) 0.86
Benchmarks for success in focal therapy of prostate cancer: cure or control? World J Urol (2010) 0.86
Sonablate-500: transrectal high-intensity focused ultrasound for the treatment of prostate cancer. Expert Rev Med Devices (2006) 0.85
Rectal fistulae after salvage high-intensity focused ultrasound for recurrent prostate cancer after combined brachytherapy and external beam radiotherapy. BJU Int (2008) 0.85
Role of alpha-blockers in type III prostatitis: a systematic review of the literature. J Urol (2007) 0.85
Lower urinary tract symptoms in men: self-perceptions and the concept of bother. BJU Int (2005) 0.84
Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway. Urol Oncol (2013) 0.84
Whole-gland salvage high-intensity focused ultrasound therapy for localized prostate cancer recurrence after external beam radiation therapy. Cancer (2011) 0.84
MR to ultrasound image registration for guiding prostate biopsy and interventions. Med Image Comput Comput Assist Interv (2009) 0.83
A comparison of the accuracy of statistical models of prostate motion trained using data from biomechanical simulations. Prog Biophys Mol Biol (2010) 0.83
The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int (2009) 0.83
Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series. BJU Int (2011) 0.82
The thermo-expandable metallic stent for managing benign prostatic hyperplasia: a systematic review. BJU Int (2006) 0.82
Urachal tumour: clinical and radiological features of a poorly understood carcinoma. Ann R Coll Surg Engl (2007) 0.82
Does photodynamic therapy have the necessary attributes to become a future treatment for organ-confined prostate cancer? BJU Int (2005) 0.81